Try our Advanced Search for more refined results
Life Sciences - November, 2023
306 articles
- DeSantis, Newsom Square Off Over Healthcare In Fox Debate
- Pfizer Overhyped Its COVID-19 Vax Efficacy, Texas AG Claims
- IP Forecast: Beauty And The Copyright-Protected Beast
- SEC Waives $40M Fine For Mallinckrodt In Medicaid Scheme
- Premera Launches Fresh Takeda Antitrust Suit Over IBS Drug
- Sorrento Gets OK For 5-Month Ch. 11 Wind-Down
- Ex-Devos CEO Must Pay $103M Over Drug Refund Scheme
- Invisalign Customers Get Class Certification In Antitrust Suits
- Clinics Sue To Block Wash. AG 'Abortion Pill Reversal' Probe
- Ohio Panel Won't Hold Drug Testing Co. Liable For Fatal Crash
- Drug Cabinet Finger Scans Are BIPA-Exempt, Ill. Justices Say
- FDA Shares New Info To Help Carry Out Food Traceability Rule
- FDA Promotes Chief Scientist To Deputy Commissioner
- What Lawyers Must Know About Calif. State Bar's AI Guidance
- Industry Must Elevate Native American Women Attys' Stories
- The Fed. Circ. In Nov.: Factual Support And Appellate Standing
- 11th Circ. Orders New Trial In Pill Mill Row Over Ruan
- Justices Told PTAB's Ax Of Ventilator Patent Was Wrong Call
- Republican AGs Assail Abortion Coverage Law At 9th Circ.
- Wachtell Lipton Guiding AbbVie On $10.1B ImmunoGen Buy
- Fed. Circ. Told To Defer To ITC In Apple Watch IP Row
- House Told AI Is A Tool, Not A Decision Maker, In Health Care
- Investors Say Co. Lied About Ultrasound Tech Prior To Merger
- Eli Lilly Partners With Prism BioLab In Deal Worth $660M
- New York Electric Utility Escapes Insurer's $3.7M Lab Fire Suit
- Pharma Co. Says 'Ulterior' Aim Shouldn't Kill Records Suit
- White House Activity Is A Band-Aid For Regulating AI In Health
- Drug Giants Face 3rd RICO Suit In 3 Weeks Over Insulin Prices
- How New Expert-Witness Rules Put Science Front And Center
- AbbVie Tells 3rd Circ. 'Sham' Case Ruling 'Explodes' Privilege
- Understanding Discovery Obligations In Era Of Generative AI
- Insurers Escape Allergy Treatment Groups' Antitrust Claims
- Biotech Co.'s Counterclaims Against Ex-Exec Trimmed
- UCLA Study Finds Calif. Teens Can't Get Plan B At Pharmacies
- Drugmakers Argue Double Patenting Ruling Defies Congress
- Group Says Doctor COVID-19 Disinformation Suit Isn't Moot
- Mich. Health Dept. Asks 6th Circ. To Back Baby Blood Program
- Daiichi Awarded $46M Fees In Cancer Drug Patent Arbitration
- Sanctioned Wholesaler Wants Abbott Labs Out Of Her Trust
- Rep. Eshoo On Retiring: 'Health Care Has Been My North Star'
- USPTO Wants Antibody Patent Case Sent Back For Review
- Fajr Capital-Led Consortium Paying $1B For Aster's Gulf Biz
- Sens. Question Anesthesia Co.'s 'Monopolistic' Model
- Law Firm Leaders Cautiously Optimistic Heading Into 2024
- The 2023 Law360 Pulse Leaderboard
- Bristol Myers Strikes Up To $2.3B Avidity Cardio Partnership
- Levi, Pomerantz Seek To Lead Insulin Pump Co. Investor Suit
- Amicus Groups Tell High Court To End Chevron Deference
- HHS' OIG Finds Low Risk Of Misuse For Opioid Treatment Drug
- Regeneron False Claims Act Case Paused Amid Appeal
- PTAB Denies Review Of Univ. Of Texas System Cancer Patent
- Arthrex Gets PTAB To Strike Down More P Tech Patents
- Teva, Eli Lilly Call Off Infringement Suit Over Migraine Drug
- Longhorn Vaccines Urges Vidal To Ax PTAB Sanctions Order
- FDA Quits Global Med Device Regulatory Group
- Kochava Ruling May Hint At Next Privacy Class Action Wave
- Forecasting The Impact Of High Court Debit Card Rule Case
- Indian Glycine Co.'s Waffling Justifies Penalty Duties
- Holdouts In Alexion Insider Trading Case Get May Trial Date
- ESG Around The World: Mexico
- Pharma Cos. Taking Discovery Disputes To Alabama Judge
- Nurse Practitioner Pleads Guilty To $4M Medical Scheme
- FDA And Companies Must Move Quickly On Drug Recalls
- Catching Up With Delaware's Chancery Court
- Dems' Victory Lap: Michigan's Biggest Legislation Of 2023
- Full Fed. Circ. Warned Of Fallout From Double Patenting Case
- FDA Rule Calls For 'Dual' Sharing Of Side Effects In TV Ads
- Debevoise Attys On AI Potential In Health, 'Iterative' Mistakes
- FDA Resource Latest Move To Prevent Baby Formula Scarcity
- COVID Tolling Fight Splits Mich. Judges, Spurs 'Histrionics'
- Pharma Co.'s Complaint Is Over Nonexistent Recall, FDA Says
- IPO Market Still Kicking As End Of 2023 Draws Near
- Bioverativ Class Seeks Sanctions For Insiders' Trades
- The Case For Post-Bar Clerk Training Programs At Law Firms
- LG Chem Hit With NC Suit Over 'Exploding' E-Cigarette Battery
- Mifepristone Ruling Risks 'Profound Disruption,' Justices Told
- Would Ending Chevron Deference Really Make Waves?
- FTC, Calif. Hit Ancestry Co. Over Deceptive Marketing, Billing
- AbbVie Says Rivals' Rinvoq Generics Infringe 34 Patents
- Alcon's $1.2M Sanctions Fee Bid For Its MoFo Attys Slashed
- FTC Warns Of Harms In Mylan Dispute With Sanofi
- Dermatology Drug Developer Can Tap $3M Of Ch. 11 Loan
- Chinese Drug Co. Wants J&J Conspiracy Claim Tossed
- Purdue Fight Over PTAB Delay Came Too Late, Fed. Circ. Says
- Chickasaw Seek Movement From Optum In Rx Payback Suit
- Allergy Testing Co. Head Charged In $5.9M Fraud Scheme
- A Telecom Attorney's Defense Of The Chevron Doctrine
- Baltimore Merck Vax Suit Proceeds But Utah, Idaho Claims Cut
- What's At Stake In Bystolic 'Side Deals' Litigation
- PE Firm, Anesthesia Practice Ask To Toss FTC Antitrust Case
- Amyris Woos 16 Bidders For Consumer Brands, Nears Auction
- Drug Giants Face New Racketeering Suit Over Insulin Prices
- 2 HHS Warnings Highlight Anti-Kickback Risks For Physicians
- Ex-Aegerion Rep Cops To Fraud, Avoiding Trial Redo
- Attorneys Have An Ethical Duty To Protect The Judiciary
- Attys Want $4.2M In Fees For Aurora Health Privacy Case
- Eli Lilly Gets ITC To Launch Probe Into Diabetes Drug Imports
- DEA Public Disclosure Process 'Kafka Like,' Texas Atty Claims
- Takeda Escapes Antitrust Suit Over IBS Drug
- Merck Buying Caraway Therapeutics For Up To $610M
- ITC Says Apple Goes 'Too Far' In AliveCor Smartwatch Dispute
- Cross-Market Implications In FTC's Anesthesia Complaint
- Colo. Says 11th Amendment Shields It From Teva EpiPen Suit
- SEC 'Shadow Trading' Case Survives Exec's Early Win Bid
- Invisalign Antitrust Classes Win Some, Lose Some On Cert.
- Ousted HR Exec Claims Life Sciences Co. Fired Her For Age
- Pharma Co. RevitaLid Approved For Ch. 11 Equity Swap Plan
- Drugmaker Tells NC Court Director Took Trade Secrets To Rival
- Catching Up With Delaware's Chancery Court
- USPTO's Vidal Sends Denied Biotech IPR To Review Panel
- Dermatology Drug Developer Hits Ch. 11 With Sale Plan
- Taylor English Defeats Bid To Revive Malpractice Claim In Ga.
- 'Immature Sniping' Sparks Sanctions Threat In Humana Spat
- Del. Jury Says NanoString Owes $31M In 10x Patent Spat
- FDA's Lack Of Power May Limit FTC's Patent Challenge
- Judge Won't Delay Ruling If States Can Join Abortion Pill Suit
- AmerisourceBergen Escapes Investor Drug-Dregs Suit In Del.
- 1st Circ. To Review Crucial Issue In Teva, Regeneron Cases
- Chancery Grants Full $18M 'Mootness' Fee To Politan Counsel
- Chancery Refuses Toss Of Biotech Firm Share Award Suit
- Centene Board Got No Red Flags On Pricing, Del. Court Told
- Vidal Revives Sleep Disorder IP Fight For More Fintiv Analysis
- Biotech Co. Will Pay $400K For Bribes, Faces No Prosecution
- Kenvue Should Have Raised FDA Probe Before IPO, Suit Says
- Danaher's $5.7B Abcam Buy Gets The Green Light To Close
- Novartis, Amgen Migraine Drug Worsened Seizures, Suit Says
- Fraud, Abuse Remain Top HHS Challenges, Watchdog Says
- Exact Sciences Launches Patent Suit Over Colon Cancer Test
- Former Acting FDA Commissioner Woodcock To Retire In 2024
- Mask Cos. And Insurer Resolve N95 Coverage Dispute
- 3 Texans Convicted In $145M Health Care Fraud
- Health Care Holding Biz To Go Public Via SPAC Merger
- Feds Drop Price-Fixing Case Against Former Drug Exec
- Vaccine Maker Novavax Appoints New COO, CLO
- Houston 'Pill Mill' Operators Sentenced To Federal Prison
- FTC Orange Book Move Signals New Pharma Patent Scrutiny
- Munger Tolles Beats DQ Bid In GenapSys' Paul Hastings Suit
- AI Can Help Lawyers Overcome The Programming Barrier
- Calif. Prosthetics Co. Says Sales Manager Stole Trade Secrets
- Taxation With Representation: Skadden, Goodwin Procter
- Anti-Abortion Lawmakers Urge Justices To Skip Pill Ruling
- Del. Arbitration Check Ordered For Insys Trustee CEO Claims
- Florida Pharmacy Settles Fraud Claims For $800K
- Judge Orders Utah Dietary Product Maker To Destroy Goods
- Ohio Justices Ask How Saving Abortion Access Affects Ban Bid
- Pharma Compliance Exec Gets 4 Yrs For $50M Medicare Fraud
- How Legal Teams Can Prep For Life Sciences' Tech Revolution
- Judge Says Breast Milk TM Dismissal Bid Was Minutes Late
- Fed. Circ. Says Medtronic Can't Revive Patent Challenge
- Illinois Seeks To Rejoin Narcolepsy Drug Overcharge Suit
- Del. Justices Uphold Merck's Post-Bayer Sale Talc Liability
- Alexion Investors Want $31M Atty Fee In Sales Tactics Deal
- FDA Warns Shops Over E-Cig Items Allegedly Aimed At Kids
- Cancer Drug Co. Says Efficacy Talk Didn't Mislead Investors
- Arnold & Porter Adds Ex-Assistant US Atty From Foley Hoag
- 3 Men Sentenced To Jail In $54M Drug Kickback Scheme
- Post-AIA Patents Cleared To Ignore 2015 Prior Art Precedent
- Ariz. Co. Banned From Making Unapproved Contraceptives
- 3 States Slam Feds' Request For Pause In Abortion Drug Suit
- Insurer Says Amryis' Ch. 11 Plan Missing Info On $800K Bonds
- Bausch Health Hit With $75M Suit Alleging Botched Drug Deal
- Medical Services Co. Sues Chase Over Defamatory 'Blacklist'
- Biopharmaceutical Co. To Go Public Via All-Stock Merger
- Union Health Care Plans File Antitrust Action Against Takeda
- Preparing Law Students For A New, AI-Assisted Legal World
- Seattle Startup Wins $83M In IP Spat With Silicon Valley Rival
- Siemens Paying $2.3B As Part Of India Energy Restructuring
- Judge Grants Eli Lilly Injunction In Mounjaro Trademark Case
- Del. Judge OKs Bidding Procedures In Zymergen Ch. 11
- 7 Women Join Texas Suit To Clarify Scope Of Abortion Ban
- Texas Judge Defers Ch. 11 Rulings Pending Recusal Hearing
- Express Scripts Wants Class Bid Cut In Acthar Case
- House Members Eye Bringing Psychedelic Treatment To Vets
- Apple Blasted For Pausing IP Cases 'Over A Hundred Times'
- Cannabis Patent Case Trimmed, Gene Pool Tells Court
- 6th Circ. Won't DQ Special Master Over 'Reply-All' Email
- ESG Around The World: South Korea
- General Counsel Need Data Literacy To Keep Up With AI
- BXP, Norges Close Boston Science Lab Deal At $1.7B Value
- Florida Duo Cops To $1.5M Medicare Fraud In Ga. Court
- PostMeds Slapped With Another Suit Over Data Breach
- House Rules Committee Tussles Over HHS Funding Bill
- Jill Biden To Steer New Women's Health Research Initiative
- Korean Device Maker Scores $1.7M Win Against Conn. Co.
- Polsinelli Bolsters Public Policy Practice With 2 Hires
- Worker Says Washington Managers Liable For Shorting Wages
- Ice Miller Guides Ohio Co.'s $620M Sale To Japanese Biotech
- Med Supplier Aeroflow Wins Fees From 'Unreasonable' IP Row
- USPTO Urges Supreme Court To Deny Fintiv Review
- Catching Up With Delaware's Chancery Court
- Bradley Arant Adds Ex-McDermott Atty To Health Care Team
- Novartis Can't Dodge Sales Rep.'s Gender Bias Suit
- Ex-Aegerion Rep. Strikes Deal To Avoid 2nd Fraud Trial
- Justices Pass On Nurses' Challenge To NJ Vaccine Mandate
- Paul Clement's Big Idea: Overrule Chevron, Ease Polarization
- Novo's Suit Over Compounded Weight-Loss Drug Is Tossed
- AARP, Others Bash AstraZeneca's Drug Pricing Challenge
- Senators Told That AI Is Already Harming Patients
- Latham, Cooley Lead Cargo Therapeutics $281M IPO
- Drug Lab Brass Face Investor Suit Over DOJ Primate Probe
- Point Biopharma Investor Sues For Info On Lilly's $1.4B Buy
- Regeneron Hits Rival With Patent Suit Over Eye Med Generic
- Abortion Foes Challenge Voter-Approved Amendment In Mich.
- Trending At The PTAB: Administrative Procedure
- Rite Aid's Reasons For Ch. 11 Go Beyond Opioid Suits
- Deals Rumor Mill: Shein, Siemens, BioMarin
- Repeal Of Mich. Drugmaker Liability Shield Goes To Governor
- Navigating Discovery Of Generative AI Information
- Ohio Jury Finds CR Bard Didn't Reveal Hernia Mesh Risks
- Drug Maker Calls DEA Admin Judge Appointment Flawed
- Nursing Home Co. Loses Some Defenses In False Claims Case
- FDA's Lab-Developed Test Rule May Bring Historic Challenges
- Gilead Wants HIV Drug Antitrust Suit Tossed Again, For Good
- Justices Told To Ignore Group's Take On Abortion Pill OK
- Finding Focus: Strategies For Attorneys With ADHD
- A Look At DOJ's New Nationwide Investment Fraud Approach
- Pharmacies Fight Tribe's Bid To Lift Stay In Payback Dispute
- Naomi Watts Says Amyris Owes Her For Work on Wellness Co.
- McCarter & English Wants $6.8M, Skewers Ex-Client's Words
- EQRx Investor Sues In Del. For Docs On Battered SPAC Deal
- Precigen's $13M Investor Settlement Gets Final Green Light
- Abbott Says It Is Not Implicated In Baby Formula MDL
- Apple Argues AliveCor's PTAB Stay Bid Is Different And Unfair
- Abbott Labs Wants To Ditch Glucerna Class Claims
- AmerisourceBergen Trims But Can't Beat Feds' Opioid Suit
- Ga. Justices Hint Health Agency Decision Exceeded Authority
- 9th Circ. Affirms Ax Of Calif. Glyphosate Cancer Warning Label
- FTC Challenges Asthma Product Patents Listed With FDA
- Fed. Circ. Judge Casts Doubt On Sweetener Enzyme Patents
- Trans Adults, Youth Tell 11th Circ. To Uphold Stay on Fla. Ban
- Amgen Seeks To Toss Investor Claims Of $10B Hidden Tax Bill
- Fed. Circ. Shoots Down Appeal In Eye Drug Patent Fight
- Va. County Alleges Racketeering In Suit Over Insulin Prices
- Senate Confirms Monica Bertagnolli As NIH Director
- Christian Clinic Says New Evidence Shows Standing In Appeal
- The 2023 Law360 Prestige Leaders
- How Law Firms Build And Protect Stellar Reputations
- Ex-Perkins Coie Atty DQ'd From Defending PacBio In IP Fight
- SmileDirectClub Says Invisalign Maker Wants It 'To Disappear'
- HRSA Unlawfully Limited Drug Discount Program, Judge Says
- Drug Discount Program Crosses US Law, Pharma Lobby Says
- AstraZeneca Must Face Sales Reps' Pay Bias Suit
- Ga. Doc To Pay $225K To Settle FCA Suit Over 'Upcoding'
- Texas Balks At HHS Mootness Argument In Abortion Pill Row
- 3 States Ask To Join Suit To Halt Access To Abortion Drug
- Catching Up With Delaware's Chancery Court
- CMS Pushes To Boost Medicare Advantage Competition
- Drug Compounding Co. Sues FDA Over 'Catch-22' Recall Ask
- Walgreens Hit With Investors Suit Over Opioid Epidemic
- Carl Sagan Estate Says Infringer Deleted Evidence On Website
- Earnout Contract Considerations After NC Good Faith Ruling
- Puerto Rico Drug Distributor Fined $12M For Opioid Failures
- Fed. Circ. Gives Viatris 2nd Shot In Actelion Patent Fight
- Winston & Strawn Accused Of Filing 'Duplicative' Pharma Suit
- Bristol-Myers To Buy Orum's Cancer Treatment Program
- FDA's Off-Label Comms Guidance Is A Reluctant Step Forward
- Justices Rebuff Opioid Doctor's Quest For 2nd Round
- Justices Grant Purdue Creditors Separate Argument Time
- Ex-FDA Regulator, J&J Exec Returns To Arnold & Porter In DC
- Gilead Sues To Reclaim Convicted Ex-CFO's $4M Legal Fees
- 'Devil's In The Details' Of Biden's AI Health Plans, Experts Say
- Fla. Lab To Pay $1.2M For Drug Test Referral Kickbacks
- Teva Investors Win Class Cert. In Drug Kickback Suit
- Reata Inks $45M Deal With Investors Over Failed Drug
- DuBois Hit With $2M Contract Verdict But No Infringement
- Abbott Gets Some DexCom Patent Claims Wiped Out
- IP Hires: Bracewell, Proskauer
- ITC Partly Ends Review Of Drug Device Imports
- Judge Says Honeywell Wants Too Much In Early IP Suit
- Pacira Hits Rivals With False Ad Suits Over Pain Drugs
- UK Litigation Roundup: Here's What You Missed In London
- Amazon Targets Counterfeit Brain Supplement Sellers
- Feds Plan $9B In Remedy Payments After Drug Discount Fight
- How Biden's AI Order Stacks Up Against Calif. And G7 Activity
- Reading Between The Lines Of HHS' National Lab Opinion
- Synlab Boards Won't Lean On Whether $1.3B Buyout Is Fair
- ITC Ban On Apple Watch Could Still Be Reversed
- Bradley Arant Atty Exits With No Sanctions Over Her Texting
- Tech Co. To Lose Kilpatrick Attys Over 'Financial Burden'
- J&J Bankruptcy May Spark SCOTUS 'Texas Two-Step' Scrutiny
- Monteverde Seeks $5M In Fees From Oclaro Investor Deal
- Cooley, Paul Hastings Steer Gene Therapy Firm's $100M IPO
- HHS Hits Back At AstraZeneca's Challenge To Drug Price Rule
- Nonprofit Calls For CMS-Amgen Price Talks To Reflect Abuse
- Firms Ask 1st Circ. To Force Ruling In Fee Row After 5 Years
- Medical Gear Co. Whistleblower Mostly Slips Counterclaims
- States Want Generic Drug Price-Fixing Claims Back In Conn.
- Reproductive Health Act Passes Michigan House
- Noteholders Want Biotech Co.'s Ch. 11 Circumstances Probed
- Fla. Abortion Access Ballot 'Hoodwinks' Voters, AG Says
- 25 AGs Want Warning Labels On Oxygen-Reading Devices
- Moderna Blasts Pfizer Bid To Add Defense To Patent Row
- A Closer Look At Proposed HHS Research Misconduct Rule
- Myovant, Sumitomo Call Alleged Skadden Conflict Public Info
- Abbvie Sued In Ill. For Probing Applicants' Medical Histories
- Incontinence Drug Ruling Offers Key Patent Drafting Lessons
- Urologist Sold Defective Penile Implants, Patient Alleges
- AbbVie Bet To Swap Parkinson's Patent Claims Fails At PTAB
- FDA Beats Alvogen Suit Over Xifaxan Skinny Label Rejection
- Acuitas Fights To Keep COVID-19 Biotech IP Suit Alive
- Barnes & Thornburg Adds Environmental Pro In Grand Rapids
- Why Hemp-Synthesized Intoxicants Need Uniform Regs
- Life Sciences Regulators Must Write Cloud-Specific Guidance
- Bradley Arant Atty Accused Of Texting Witnesses Seeks Exit
- Fed. Circ. Elekta Holding May Make Patent Prosecution Harder
- Attorneys, Law Schools Must Adapt To New Era Of Evidence